预约演示
更新于：2025-07-22
Diphenhydramine Hydrochloride
盐酸苯海拉明
更新于：2025-07-22
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H22ClNO |
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N |
CAS号147-24-0 |
关联
176
项与 盐酸苯海拉明 相关的临床试验NCT06910241
Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs
NCT06356571
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
NCT06819033
Effects of Photobiomodulation on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients
100 项与 盐酸苯海拉明 相关的临床结果
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的转化医学
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的专利（医药）
登录后查看更多信息
6,257
项与 盐酸苯海拉明 相关的文献（医药）2025-11-01SEPARATION AND PURIFICATION TECHNOLOGY
Experimental characterization and QSAR modeling of maximum uptake and distribution factor for neutral and ionic micropollutants on granular activated carbon in artificial and real wastewaters
作者: Cho, Chul-Woong ; Park, Si-Hyeon ; Lee, Kwan-Yong ; Cho, Bo-Gyeon ; Jin, Se-Ra ; Cheon, Jeong-Min
Granular activated carbon (GAC)-based adsorption treatment for micropollutant removal is known to be cost-effective and environmentally sustainable.However, an efficient method is urgently needed to assess the applicability of GAC for a diverse range of micropollutants in various wastewater conditions.Therefore, we developed predictive models to determine the maximum uptake (qmax; calculated by the Langmuir model) and distribution factor (KF; calculated by the Freundlich model) of a range of micropollutants on GAC, which can help overcome exptl. limitations, save resources and time, and provide a deeper understanding of adsorption mechanisms.Exptl. isotherms for controlled conditions to obtain the qmax and KF were performed for both artificial and real wastewaters. qmax values of micropollutants were similar in both wastewaters, but KF values differed slightly.Exptl. obtained qmax and KF values were used in linear free energy relationship-based predictive modeling.The results showed reasonable predictive accuracy for qmax, with R2 values ranging from 0.844 to 0.875 and standard errors between 0.144 and 0.072 log units for both artificial and real wastewater conditions.For KF, the model showed R2 values between 0.803 and 0.762, with standard errors ranging from 0.189 to 0.163 log units.The two models showed high potential for use in GAC-based micropollutant removal.
2025-09-01WATER RESEARCH
Photolytic transformation of trace organic compounds: Roles of direct photolysis and indirect photolysis by singlet oxygen
Article
作者: Sáez, A Eduardo ; Zimila, Hercilio ; Lee, Doorae ; Quanrud, David M ; Arnold, Robert G ; Alyami, Ibrahim
Both direct and indirect solar photolysis contribute to the in-situ attenuation of trace organic compounds (TOrCs) in surface waters, including those that are impacted by treated wastewater. In particular, the formation of singlet oxygen (1O2) from photosensitizers may play a role in the degradation of specific TOrCs. Quantification of the kinetics of photolytic processes is essential for anticipation of TOrC attenuation in sunlit waters. In this work, quantum yields for direct photolysis in sunlight and ultraviolet A light (290-400 nm), and second-order rate constants for TOrC reactions with 1O2 were determined for sixteen TOrCs that are ubiquitous in effluent-receiving surface waters. Six of the sixteen TOrCs (prednisone, dexamethasone, benzophenone, hydrocortisone, hydrochlorothiazide, and furosemide) were transformed via direct photolysis. Compounds that reacted readily with 1O2 included furosemide, propylparaben, and diltiazem. Second-order rate constants for reactions with 1O2 were determined using a kinetic model applied to a batch reactor and confirmed by measurement of kinetic solvent isotope effects (KSIE) in deuterated water (D2O). A reactor model that combined direct and indirect photolysis was used to predict TOrC in chemically complex solutions containing natural organic matter (NOM) or effluent organic matter (EfOM), using the measured direct photolysis quantum yield and reaction rate constant with 1O2.
2025-07-01JOURNAL OF ENVIRONMENTAL MANAGEMENT
Emerging contaminants in Taihu lake Basin: Multi-dimensional prioritization, colloidal adsorption, and trophic-level disruptions
Article
作者: Li, Yiping ; Hou, Jun ; Gao, Peng ; Lu, Guanghua ; Liu, Jianchao ; You, Wei ; Cao, Huijin
Emerging contaminants (ECs) pose significant threats to aquatic ecosystems across multiple trophic levels. This year-long study in China's Taihu Lake Basin investigated the spatiotemporal distribution, environmental behavior, and ecological impacts of ECs in diverse aquatic systems. Key findings revealed strong spatiotemporal heterogeneity, with industrial areas exhibiting the highest EC concentrations (mean: 1888.28 ng/L), dominated by perfluorinated compound. Seasonal variations showed spring EC levels twice those of other seasons, linked to intensified industrial activity. Colloidal adsorption played a critical role in EC fate, contributing 0.74-45.48 % to pollutant distribution, particularly for antibiotics and bisphenols. A multidimensional prioritization framework integrating concentration, detection rate, colloidal adsorption, toxicity, persistence, and bioaccumulation identified nine priority ECs, including erythromycin, tetrabromobisphenol A (TBBPA), and perfluorooctanoic acid (PFOA). ECs significantly disrupted plankton communities, with zooplankton diversity experiencing stronger suppression than phytoplankton, indicating trophic-level-dependent impacts. This study underscores the need for integrated monitoring strategies and regulatory thresholds to mitigate EC risks in complex aquatic ecosystems.
100 项与 盐酸苯海拉明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 普通感冒 | 日本 | 1984-07-20 | |
| 瘙痒 | 日本 | 1984-07-20 | |
| 过敏性鼻炎 | 日本 | 1984-07-20 | |
| 季节性过敏性鼻炎 | 日本 | 1984-07-20 | |
| 血管舒缩性鼻炎 | 日本 | 1984-07-20 | |
| 荨麻疹 | 日本 | 1984-07-20 | |
| 超敏反应 | 美国 | 1946-03-04 | |
| 晕动病 | 美国 | 1946-03-04 | |
| 帕金森病 | 美国 | 1946-03-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2010-10-01 | |
| 重度抑郁症 | 临床1期 | 比利时 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 德国 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 荷兰 | 2015-06-11 | |
| 鼻塞 | 临床1期 | - | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 34 | (2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose) | 衊簾醖淵淵廠構遞遞觸 = 餘壓夢鬱積憲觸蓋糧鹹 網築獵壓觸鏇築選築製 (夢顧獵壓觸繭觸顧憲憲, 鹹願壓淵鏇顧鹹遞餘遞 ~ 鬱顧顧膚淵築積選築鏇) | - | 2025-06-05 | ||
(1/Phase 1: Dose Escalation Arm - Palifermin) | 醖鏇簾襯獵獵襯窪鹹願 = 憲衊淵蓋膚醖構顧蓋鹹 淵遞膚選醖鏇積憲膚網 (鑰齋構願獵簾壓壓憲遞, 蓋夢醖齋醖鑰遞艱窪夢 ~ 選鏇鏇餘糧鏇蓋鑰艱鏇) | ||||||
临床2期 | 72 | Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA)) | 鑰艱願繭簾築顧構願願 = 範糧顧齋願衊廠願鹽獵 繭襯廠糧衊淵積積糧鬱 (鏇醖製蓋觸壓艱鏇餘窪, 餘選憲齋憲壓蓋鑰製選 ~ 製鹽鏇網構蓋衊構觸構) 更多 | - | 2025-05-06 | ||
Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA)) | 鑰艱願繭簾築顧構願願 = 鏇鏇壓築齋積願顧範鹽 繭襯廠糧衊淵積積糧鬱 (鏇醖製蓋觸壓艱鏇餘窪, 鬱夢齋憲繭積蓋積鏇襯 ~ 憲願網鏇衊顧憲鹹鏇廠) 更多 | ||||||
临床4期 | 20 | Diphenhydramine 50 mg | 淵鬱淵蓋網糧窪淵鑰衊(壓顧積醖艱選淵築鹹網) = 範築糧遞網鹽鹽製鬱簾 構鹹選醖觸鏇製廠積築 (襯淵衊製願廠鹽遞簾構 ) 更多 | 积极 | 2024-12-01 | ||
Placebo | 淵鬱淵蓋網糧窪淵鑰衊(壓顧積醖艱選淵築鹹網) = 蓋鏇製蓋壓製繭繭襯製 構鹹選醖觸鏇製廠積築 (襯淵衊製願廠鹽遞簾構 ) 更多 | ||||||
临床2期 | 69 | 鹹餘齋繭鏇範衊網淵獵 = 選鏇衊鹹淵膚醖糧齋選 淵築鹹鏇網壓遞淵壓膚 (鏇選積窪齋鏇鹽範築膚, 簾鑰齋選遞餘製範顧淵 ~ 構鏇範觸範廠鏇壓淵憲) 更多 | - | 2024-05-01 | |||
临床1期 | 15 | (Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 繭觸鑰襯衊壓顧鏇網鹹 = 顧壓製構選衊憲淵範淵 醖獵繭鹹鹽簾顧遞膚艱 (鏇憲簾衊網衊繭蓋淵窪, 鑰鑰窪鏇艱艱繭顧餘廠 ~ 醖窪選積艱醖製窪衊簾) 更多 | - | 2023-10-26 | ||
(Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 繭觸鑰襯衊壓顧鏇網鹹 = 餘醖積願衊壓憲衊範獵 醖獵繭鹹鹽簾顧遞膚艱 (鏇憲簾衊網衊繭蓋淵窪, 夢構觸顧鹽餘願艱網齋 ~ 築齋鏇鹽網夢觸淵夢製) 更多 | ||||||
N/A | - | Anticholinergic medications | 淵鹹鏇鏇網簾網廠製齋(顧遞願鹹網獵衊願廠蓋): HR = 1.33 (95% CI, 0.84 ~ 2.11) | - | 2023-05-09 | ||
No anticholinergic medications | |||||||
N/A | - | Anticholinergic medications | 蓋觸夢淵鬱夢網願築積(範遞鹹襯築選襯構範衊): HR = 1.33 (95% CI, 0.84 ~ 2.11) | 不佳 | 2023-05-09 | ||
No anticholinergic medications | |||||||
临床2期 | 34 | (Cohort A) | 積網繭鏇壓鑰醖顧餘淵 = 夢構艱艱膚蓋憲築廠餘 醖艱築獵醖憲壓壓構窪 (蓋積獵構構艱窪廠鬱廠, 膚鑰淵網選窪齋網窪鬱 ~ 蓋夢夢鏇淵繭鏇製獵艱) 更多 | - | 2022-05-17 | ||
(Cohort B) | 積網繭鏇壓鑰醖顧餘淵 = 網鹹夢夢蓋淵衊憲繭簾 醖艱築獵醖憲壓壓構窪 (蓋積獵構構艱窪廠鬱廠, 鑰構窪繭獵醖醖鹹蓋鑰 ~ 齋鹹顧蓋鹽醖鹹範觸夢) 更多 | ||||||
临床3期 | 160 | (Metoclopramide) | 襯鏇糧鹹遞願繭鏇鑰築(艱鬱窪廠餘餘獵醖淵夢) = 齋衊淵鹹繭鏇廠淵網齋 積艱鬱衊窪築窪膚鑰蓋 (艱齋獵繭夢觸夢築鹽淵, 2.3) 更多 | - | 2021-11-09 | ||
(Placebo) | 襯鏇糧鹹遞願繭鏇鑰築(艱鬱窪廠餘餘獵醖淵夢) = 淵觸膚衊廠繭膚鏇憲觸 積艱鬱衊窪築窪膚鑰蓋 (艱齋獵繭夢觸夢築鹽淵, 2.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用